Long-term survival following hematopoietic cell transplantation (HCT) is dependent on the eradication of primary disease and the rapid restoration of durable hematopoiesis and immune competence. Despite more precise HLA typing, novel cytoreductive regimens, and improved methods to detect and treat opportunistic pathogens, infection, with or without GVHD, remains the primary cause of transplant mortality in patients lacking an NLA-matched sibling. The purpose of this core is to provide a centralized program to monitor the effect of transplant regimen, donor and stem cell source (bone marrow, peripheral blood, cord blood), use of adoptive immunotherapy, and immunomodulatory growth factors (IL-7, KGF) on the kinetics of immunologic reconstitution, donor/host chimerism, and disease recurrence following allogeneic HCT. This core will longitudinally assess the quality and tempo of immunologic reconstitution following TCD related or unrelated PBSCT or unrelated double cord blood HCT by assessing the phenotype and/or function (proliferation, cytotoxicity, antibody production) of the recovering monuclear cell populations, including NK, T and B lymphocytes, monocytes, and dendritic cells. It will monitor the recovery of recent thymic emigrants, regulatory T cells, dendritic, and monocyte subpopulations by four color immunofluorence and presence of T cell receptor exicion circles (TREC). This core will be responsible for tetramer production used to analyze the reconstitution of circulating antigen-specific T cells following infusion of viral or WT1 specific cytotoxic T cells and will assess functional recovery of these antigen specific cells (intracellular cytokine production, cytotoxicity, proliferative capacity). It will monitor the chimeric status of recovering mononuclear cell populatons and assay for minimal residual disease by minisatellite PCR analysis and detection of WT1 transcripts, respectively. These studies will help gauge the effects of stem cell source (PBSC, BM, umbilical cord blood), donor selection (HLA-matched related, mis-matched related, or unrelated), use and method of T cell depletion, and immunomodulatory agents (interleukin-7, KGF, viral and/or tumor specific-CTLs) on the most common transplant related complications, namely relapse, regimen related toxicity, and infection. Lay abstract. Infection arid disease recurrence are significant causes of transplant failure. This core will evaluate the impact of transplant type, cytoreduction, and immunotherapy on these parameters.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Boudreau, Jeanette E; Hsu, Katharine C (2018) Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends Immunol 39:222-239
Lin, Richard J; Ho, Caleb; Hilden, Patrick D et al. (2018) Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol :
Malard, Florent; Labopin, Myriam; Cho, Christina et al. (2018) Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. J Hematol Oncol 11:127
Luduec, Jean-BenoƮt Le; Kudva, Anupa; Boudreau, Jeanette E et al. (2018) Novel multiplex PCR-SSP method for centromeric KIR allele discrimination. Sci Rep 8:14853
Shah, Gunjan L; Moskowitz, Craig H (2018) Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 131:1689-1697
Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141
Staffas, Anna; Burgos da Silva, Marina; Slingerland, Ann E et al. (2018) Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. Cell Host Microbe 23:447-457.e4
Velardi, Enrico; Tsai, Jennifer J; Radtke, Stefan et al. (2018) Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury. Nat Med 24:239-246
Moskowitz, Craig H (2018) Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv 2:821-824
Kim, Seong Jin; Huang, Yao-Ting; Foldi, Julia et al. (2018) Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients. Transpl Infect Dis 20:e12881

Showing the most recent 10 out of 452 publications